MAPT and Alzheimer disease: Moreover, the tau-targeting antisense oligonucleotide (ASO) MAPTRx has shown safety and a sustained reduction in CSF tau levels in a first-in-human phase 1b trial for patients with mild AD (NCT03186989) (Mummery et al., 2023).